The iHIVARNA Project’s 5th General Assembly Meeting has been held last 4-5 of February in the H10 Art Gallery Hotel in Barcelona. The General Assembly meetings take place twice per year and include senior representatives from each partner of the iHIVARNA project.
The meeting was focused on two main topics:
1) updating the status of the phase I clinical trial, and
2) start the preparation for the phase II clinical trial.
The first results with the first vaccinated patients are quite optimistic and the discussion on the phase II clinical trial was productive, setting the foundations for this second part of the project.
Next face-to-face meeting will take place in Brussels on June 2016.
iHIVARNA is a European multi-national research project funded by the European Commission. iHIVARNA’s project aims to successfully immunize antiretroviral-treated HIV-infected patients with an mRNA-based therapeutic vaccine, thus improving the efficacy of therapeutic vaccination against HIV infection. An additional objective of the project is to generate new knowledge for reaching the functional cure of HIV infected patients.
The project brings together the expertise of a number of European groups (Spain, Belgium, and Netherlands) in a number of fields required for an adequate development of the therapeutic vaccine (dendritic cell targeting, rational design of immunogens, mRNA manufacturing and immuno-virological monitoring, among others).
The project brings together the expertise of a number of European groups (Spain, Belgium, and Netherlands) in a number of fields required for an adequate development of the therapeutic vaccine (dendritic cell targeting, rational design of immunogens, mRNA manufacturing and immuno-virological monitoring, among others).
“The research leading to this results has received funding from the European Comunity’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 602570 – the iHIVARNA project.”
Asphalion, is an SME with expertise in projects that fall under the eligibility criteria for Horizon 2020 Programme. Asphalion is available to provide these type of projects with its regulatory expertise.
Asphalion supports research consortia as SME Regulatory Expert Partner with experience in proposal preparation and application process. Asphalion can support with the following activities: Orphan Drug Designation application, Paediatric Investigation Plan, Regulatory Roadmaps, IMPD / IB for Clinical Trials, Clinical Trial Applications, Scientific Advice / Protocol Assistance, Clinical / Nonclinical/CMC development plans, SME application to EMA. Asphalion has worked with wide variety of product types: Biosimilar, Biotech, Cell Therapy products, Gene therapy products, Herbal products, Medical Devices, Plasma derived products, Small molecule.
Asphalion supports research consortia as SME Regulatory Expert Partner with experience in proposal preparation and application process. Asphalion can support with the following activities: Orphan Drug Designation application, Paediatric Investigation Plan, Regulatory Roadmaps, IMPD / IB for Clinical Trials, Clinical Trial Applications, Scientific Advice / Protocol Assistance, Clinical / Nonclinical/CMC development plans, SME application to EMA. Asphalion has worked with wide variety of product types: Biosimilar, Biotech, Cell Therapy products, Gene therapy products, Herbal products, Medical Devices, Plasma derived products, Small molecule.
If you are interested please contact us: [email protected]
iHIVARNA: The research leading to this results has received funding from the European Comunity’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 602570
